

CORE LABORATORIES N V  
Form 8-K  
May 22, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): May 16, 2012

CORE LABORATORIES N.V.  
(Exact name of registrant as specified in its charter)  
001-14273  
(Commission File Number)  
The Netherlands  
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

Not Applicable

Herengracht 424  
1017 BZ Amsterdam  
The Netherlands  
(Address of principal executive offices)

Not Applicable  
(Zip Code)

Registrant's telephone number, including area code: (31-20) 420-3191

Check the appropriate below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

Core Laboratories N.V. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on May 16, 2012. At the Annual Meeting, the Company's stockholders were requested: (1) to elect two Class III supervisory directors to serve on the Company's board of supervisory directors for a term of office expiring at the Company's 2015 Annual Meeting of Shareholders, (2) to ratify the appointment of PricewaterhouseCoopers as the Company's independent registered public accountants for the fiscal year ending December 31, 2012, (3A) to conduct a non-binding advisory vote to approve the compensation of the Company's executive officers, (3B) to conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's executive officers, (4) to confirm and adopt the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2011, (5) to approve and resolve the cancellation of the Company's repurchased shares held by the Company in its name at the time the Annual Meeting starts, (6) to approve and resolve the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until November 16, 2013, (7) to approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 20% of outstanding shares per annum until May 16, 2017, (8) to approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 20% of outstanding shares per annum until May 16, 2017, (9) to approve and resolve amendments to the Core Laboratories N.V. articles of association in connection with the decision to list the Company's shares on the NYSE Euronext in Amsterdam and for other reasons. Each of these items is more fully described in the Company's proxy statement filed on March 21, 2012.

The certified results of the matters voted upon at the Annual Meeting are as follows:

Proposal No. 1 - Election of Class III Directors: The election of each Class III supervisory director was approved as follows:

Nominee	For	Withheld	Broker Non-Votes
Richard L. Bergmark	31,782,731	6,562,048	2,928,771
Margaret Ann van Kempen	37,348,906	995,873	2,928,771

Proposal No. 2 - Ratification of the Selection of PricewaterhouseCoopers: The ratification of the selection of PricewaterhouseCoopers as the Company's independent registered public accountants for the fiscal year ending December 31, 2012 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
41,162,907	71,803	38,840	-

Proposal No. 3A - Approve the Compensation of the Company's Executive Officers: The approval of the compensation of the Company's executive officers was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,808,173	2,498,792	37,814	2,928,771

Proposal No. 3B - Approve the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of the Company's Executive Officers: The approval of the frequency of future non-binding advisory votes to approve the compensation of the Company's executive Officers was approved as follows:

Edgar Filing: CORE LABORATORIES N V - Form 8-K

One Year	Two Years	Three Years	Abstentions	Broker Non-Votes
25,198,662	1,409,477	11,719,342	17,298	2,928,771

---

Proposal No. 4 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2011 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
37,927,515	269,771	3,076,264	-

Proposal No. 5 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at the time the Annual Meeting starts was approved as follows:

For	Against	Abstentions	Broker Non-Votes
38,321,641	4,395	18,743	2,928,771

Proposal No. 6 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until November 16, 2013 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
38,015,904	14,987	313,888	2,928,771

Proposal No. 7 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 20% of outstanding shares per annum until May 16, 2017 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,560,320	2,757,443	27,016	2,928,771

Proposal No. 8 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 20% of outstanding shares per annum until May 16, 2017 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
34,183,910	4,135,060	25,809	2,928,771

Proposal No. 9 - Approve Amendments to the Articles of Association: The approval of the amendments to the articles of association was approved as follows:

For	Against	Abstentions	Broker Non-Votes
38,304,176	26,868	13,735	2,928,771



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Core Laboratories N.V.

Dated: May 22, 2012

By /s/ Richard L. Bergmark  
Richard L. Bergmark  
Chief Financial Officer